Please assess the completion status of the following clinical trial:

Trial Title: Ondansetron Administration to Children With Gastroenteritis, Vomiting and SOME Dehydration in EDs in Pakistan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 6 - 59 months (0.5 - 5 years)~* Symptoms consistent with gastroenteritis (must have a \& b)~  1. 1 episode of nonbilious, nonbloody vomiting within the 4 hours preceding triage The requirement for only 1 vomiting episode is based on prior work which similarly required 1 vomiting episode within 4 hours of triage. The later study reported a 17% absolute reduction in the use of IV rehydration. The vast majority of children seeking care and enrolled in the aforementioned study had a significantly greater number of vomiting episodes in the preceding 24 hour (mean \>9 episodes).29~ 2. Presence of ≥ 1 episode of diarrhea during the illness We require the presence of only 1 diarrheal stool to enhance our probability of enrolling children with enteritis (as opposed to other diagnoses).~In fact, of the 8 RCTs performed using antiemetics in children with gastroenteritis in developed countries, only 1 even required the presence of any diarrhea as part of the eligibility criteria (and that study required a single diarrheal stool).~- Presence of SOME dehydration - 2 or more of the following signs: i. Restlessness, irritability; ii. Sunken Eyes; iii.Drinks eagerly, thirsty; iv.Skin pinch goes back slowly~Exclusion Criteria:~* Weight \<8 kg~* Vomiting or diarrhea for \> 7 days~* Malnutrition: The WHO definition will be employed - weight for height below -3z scores of the median WHO growth standards~* Severe dehydration (WHO criteria) or hypotension defined as a systolic blood pressure \<70 mm Hg in infants 1 month to 12 months, \< 70 mm Hg + (2 x age in years) in children 1-10 years, \< 90 mm Hg in children ≥ 10 years~* Prior abdominal surgery (excluding hernia)~* Bilious or bloody vomitus~* Known hypersensitivity to ondansetron or any serotonin receptor antagonist~* History or family history of prolonged QT syndrome~* Taking apomorphine or any medication that is generally accepted as having a risk of causing torsades de pointes~* Patients previously enrolled in the study~* Follow-up will not be possible

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 59 Months
- Healthy Volunteers: f

Study Arms:
- Ondansetron (Type: EXPERIMENTAL): 4 mg oral disintegrating tablet of ondansetron~Participant weight 8-15 kg = half dose (2mg) Participant weight greater than 15 kg = full dose (4mg)
- Placebo (sugar pill) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).